| Literature DB >> 33880197 |
Abstract
Autism spectrum disorder (ASD) is known to increase a variety of psychiatric disorders, including major depressive disorder (MDD). Acceptance and commitment therapy (ACT) has been reported to be an effective psychotherapy for MDD. However, this is not the case with ASD. In this case study, based on the hypothesis that it is effective in treating MDD with ASD, we adapted the ACT Matrix, a tool for visualizing an individual's experiences in the context of ACT, and administered 15 sessions to a woman with MDD with ASD following the onset of photo dermatosis. By the end of the final session, there was an increase in value-based behaviors and significant changes in depressive symptoms as well as significant changes in process measures such as experience avoidance, mindfulness, and progress toward a valued life. Six months after the end of the session, the improvement in symptoms was even stronger and the process measure of obstruction to a valued life was significantly improved. The ACT Matrix may thus ameliorate MDD in patients with ASD.Entities:
Year: 2021 PMID: 33880197 PMCID: PMC8046572 DOI: 10.1155/2021/5511232
Source DB: PubMed Journal: Case Rep Psychiatry ISSN: 2090-6838
Figure 1Image of hexaflex. Six interrelated core ACT processes produce psychological flexibility. These processes are (1) contact with the present moment, (2) defusion, (3) acceptance, (4) self as context, (5) values, and (6) committed action.
Figure 2The frequency of clinically relevant target behaviors consistent with the patient's values from intake to the end of sessions.
Figure 3Symptom and process measures from the intake to 6-month posttermination of sessions. QIDS-SR-J = Quick Inventory of Depressive Symptomatology Self Report-Japanese; AAQ-II-J = second version of the Acceptance and Action Questionnaire-Japanese; CFQ-7-J = Cognitive Fusion Questionnaire-7 Japanese; MAAS-J = Mindful Attention Awareness Scale-Japanese; VQ-J = Valuing Questionnaire-Japanese.
RCIs.
| Baseline (intake) | Termination (session 15) | 6 months posttermination | RCI | |||
|---|---|---|---|---|---|---|
| Intake vs. session 15 | Intake vs. 6 months posttermination | Session 15 vs. 6 months posttermination | ||||
| QIDS-SR-J | 24 | 7 | 6 | −6.56a | −6.94a | −0.39 |
| CFQ-7-J | 49 | 37 | 21 | −3.23a | −7.53a | −4.31a |
| MAAS-J | 55 | 66 | 71 | 2.55a | 3.71a | 1.16 |
| VQ-J progress | 0 | 25 | 27 | 9.16a | 9.89a | 0.73 |
| VQ-J obstruction | 26 | 25 | 13 | −0.19 | −2.44a | −2.26a |
RCI = reliable change index; QIDS-SR-J = Quick Inventory of Depressive Symptomatology Self Report-Japanese; CFQ-7-J = Cognitive Fusion Questionnaire-7 Japanese; MAAS-J = Mindful Attention Awareness Scale-Japanese; VQ-J = Valuing Questionnaire-Japanese. aClinically significant (>1.96).